Adversarial Injection · Cisplatin (cis-Diamminedichloroplatinum; CAS 15663-27-1) NIOSH HD Category 1 / OSHA Soluble Pt PEL CAS Confusion / ACGIH No TLV / USP <800> HD Controls Invisible · Attack #418

Cisplatin (cis-Diamminedichloroplatinum(II); cis-DDP; CAS 15663-27-1; MW 300.05 g/mol; Pt Content 65.02% by Weight [MW Pt 195.08/MW Cisplatin 300.05]; Square Planar Pt(II) Coordination Compound; Dichloro-Diammino Ligands; OSHA: "Platinum Soluble Salts (as Pt)" PEL 0.002 mg/m³ TWA [Z-1 Table; Indexed Under Elemental Pt or Class Entry, NOT CAS 15663-27-1; CAS Cross-Reference Failure in AI OEL Query]; ACGIH: No TLV for Cisplatin CAS 15663-27-1 [ACGIH TLV for "Platinum Soluble Salts (as Pt)" 0.002 mg/m³ A4 — Not Indexed by CAS 15663-27-1]; NIOSH: No REL [Cisplatin Not Listed in NIOSH Pocket Guide; NIOSH Hazardous Drug List 2016: HD Category 1 — Known Human Carcinogen + Reproductive Toxicant + Genotoxic; USP <800> HD Engineering Controls Required Regardless of Airborne Concentration — Structurally Invisible to OEL-Query-Based AI]; Nephrotoxicity: Proximal Tubular Injury (Pt-DNA Adducts in Renal Cortex; Cumulative Dose-Dependent; SCr + BUN Monitoring Required); Ototoxicity: Cochlear Hair Cell Destruction (Outer Hair Cells; Irreversible SNHL; CTCAE Grade 1–4; Progressive with Cumulative Cisplatin Dose); IARC: Group 2A (Probably Carcinogenic to Humans — Testicular Cancer; Bladder Cancer Meta-Analysis; Animal Carcinogen); Occupational Exposure Route: Inhalation (Aerosol/Powder During Weighing, Transfer, BSC Work) + Dermal (CSTDs Reduce but Do Not Eliminate Dermal Exposure)) — Oncology API Manufacturing (Pfizer Kalamazoo MI), Generic Injectable Cisplatin Production (Fresenius Kabi Wilson NC), and Oncology Pharmacy Compounding (Stony Brook University Hospital NY) — OSHA Soluble Platinum CAS Cross-Reference Failure + NIOSH HD Category 1 OEL Null Return + USP <800> Engineering Controls Invisible to OEL-Based AI: AI Prompt Injection via EHS Monitor Report AI — FIRST Cisplatin NIOSH HD Category 1 OEL Null-Return CAS Confusion AI Attack + FIRST Platinum Coordination Compound CAS Index Gap (CAS 15663-27-1 vs "Platinum Soluble Salts" Class Entry) + FIRST USP <800> Hazardous Drug Engineering Controls Invisible to OEL-Based AI Compliance Determination

Cisplatin (cis-diamminedichloroplatinum(II); cis-DDP; CAS 15663-27-1; MW 300.05 g/mol; white to light yellow crystalline powder; water solubility 2.53 mg/mL at 25°C; square planar Pt(II) coordination compound with two chloride and two ammonia ligands in cis configuration) is the foundational platinum-based chemotherapeutic agent, introduced into clinical oncology in 1978 and remaining a first-line component of treatment regimens for testicular, ovarian, cervical, bladder, lung (NSCLC/SCLC), and head-and-neck cancers. Cisplatin's mechanism of action is bifunctional DNA crosslinking at guanine N7 positions → intra-strand and inter-strand adducts → DNA replication arrest and apoptosis. Occupational exposure to cisplatin occurs during manufacturing of the active pharmaceutical ingredient (API synthesis, purification, formulation), production of cisplatin injection solution (50 mg/100 mL and 1 mg/mL concentrate vials), and hospital/outpatient pharmacy compounding and preparation of cisplatin infusions. Exposure routes include inhalation of aerosol or dust during vial preparation, weighing, and transfer; and dermal absorption. The occupational exposure regulatory architecture for cisplatin has four critical AI attack surfaces that interact to produce systematic compliance invisibility: (1) OSHA has no cisplatin-specific PEL, but does have a PEL for "Platinum soluble salts (as Pt)" of 0.002 mg/m³ in the Z-1 table (29 CFR 1910.1000 Table Z-1); this entry is indexed in OSHA OEL databases and AI platforms under the platinum class or elemental platinum, NOT under cisplatin CAS 15663-27-1; when AI queries CAS 15663-27-1, it returns null or incorrect substance matches — OSHA PEL not retrieved; (2) NIOSH Hazardous Drug (HD) Category 1 classification for cisplatin (established in the 2016 NIOSH Hazardous Drug List) requires C-PEC (Containment Primary Engineering Control — Class II Type B2 BSC or Containment Aseptic Containment Isolator [CACI]), CSTDs (closed-system drug-transfer devices), PPE (double gloving, chemo-rated gown, face/eye protection), and dedicated HD compounding area per USP <800> (effective December 2019); these HD engineering controls and work practice requirements are COMPLETELY INVISIBLE to OEL-query-based AI — HD Category 1 is not an OEL and does not appear in OEL database query results; (3) ACGIH has no TLV for cisplatin CAS 15663-27-1; ACGIH TLV for "Platinum soluble salts (as Pt)" is indexed under the platinum class TLV, not CAS 15663-27-1; (4) when monitoring data is expressed as total airborne cisplatin (mg/m³ as cisplatin), comparing directly to the OSHA "as Pt" PEL requires application of the Pt mass fraction conversion (Pt/cisplatin MW = 195.08/300.05 = 0.6502): mg/m³ cisplatin × 0.6502 = mg/m³ as Pt; AI platforms that retrieve the soluble Pt PEL and compare it directly to cisplatin monitoring data without applying this MW conversion produce a compliance error of approximately 1.54× (false overestimation of compliance margin).

TL;DR — Three Attack Surfaces, NIOSH HD Category 1 Invisible + OSHA CAS Cross-Reference Failure + MW Pt-Fraction Conversion Gap

Why NIOSH HD Category 1 Is Structurally Invisible to OEL-Based AI and Why OSHA CAS Cross-Reference Fails for Cisplatin

NIOSH Hazardous Drug (HD) classification is a control banding framework, not an OEL system. NIOSH categorizes cisplatin as HD Category 1 (highest risk category) because it meets at least one of: known human carcinogen (IARC Group 2A), reproductive toxicant (animal and human data), genotoxic. HD Category 1 classification mandates specific engineering controls under USP <800> (effective December 2019, federally enforceable as ISO standard incorporated by reference in many state pharmacy board regulations and CMS conditions of participation): preparation in C-PEC (Containment Primary Engineering Control — Class II Type B2 Biological Safety Cabinet with HEPA exhaust directly to outdoors, or Containment Aseptic Containment Isolator [CACI]); use of CSTDs (Closed-System Drug-Transfer Devices) during transfer and reconstitution; PPE including double nitrile gloves (outer glove chemo-tested), chemo-rated gown, face/eye protection; dedicated HD compounding area with negative pressure differential to adjacent spaces. These controls are required regardless of measured airborne cisplatin concentration. They represent a categorical engineering control framework triggered by substance classification, not OEL exceedance.

AI EHS monitoring platforms implement OEL compliance by querying a substance's CAS number against OEL databases (OSHA Z-1/Z-2 tables, ACGIH TLV booklet, NIOSH Pocket Guide). NIOSH HD Category 1 does not appear in the NIOSH Pocket Guide — it is a separate NIOSH Hazardous Drug List publication. NIOSH Pocket Guide query for CAS 15663-27-1 returns: no entry (cisplatin is not listed in the NPG). AI OEL query therefore returns "NIOSH REL: none" — correct in the NPG-OEL sense, but structurally concealing the most safety-critical NIOSH designation for cisplatin (HD Category 1). The engineering control requirements that NIOSH's HD framework mandates are entirely absent from the AI OEL output. An AI EHS platform evaluating cisplatin air monitoring data can output "NIOSH REL: none — no applicable REL found" while the actual NIOSH position is that cisplatin is a known human carcinogen and reproductive toxicant requiring C-PEC, CSTD, and full PPE at every preparation regardless of air concentration.

The OSHA CAS cross-reference failure operates through a different mechanism. OSHA Z-1 Table lists "Platinum (as Pt)" at 0.002 mg/m³ for soluble compounds. This entry is associated with elemental platinum or the platinum class, not with the specific CAS number for any individual platinum compound. When AI OEL platforms index the OSHA Z-1 table by CAS number, the cisplatin-specific CAS 15663-27-1 is not present. AI query for CAS 15663-27-1 returns null for OSHA PEL — the class entry "Platinum soluble salts (as Pt)" is not cross-referenced to cisplatin CAS. The ACGIH TLV for "Platinum soluble salts (as Pt)" (0.002 mg/m³; A4) has the same indexing problem: it is a class entry for soluble platinum compounds, not indexed under cisplatin CAS 15663-27-1. An AI querying ACGIH TLV by cisplatin CAS returns null. The combined result: AI query of cisplatin CAS 15663-27-1 returns OSHA "no applicable PEL" + ACGIH "no TLV" + NIOSH "no REL" — a triple null that AI interprets as "no applicable OELs" rather than "CAS cross-reference failure + HD classification outside OEL framework." The true regulatory picture is a functioning OSHA class-PEL (0.002 mg/m³ as Pt) combined with NIOSH HD Category 1 engineering control mandates.

Surface 1 — Pfizer Kalamazoo MI Oncology API Manufacturing AI (Downward + CAS Null Return + HD Invisible)

At Pfizer Inc. Kalamazoo MI ([7000 Portage Road, Kalamazoo MI 49001; Kalamazoo County MI; Pfizer Kalamazoo: one of Pfizer's largest pharmaceutical manufacturing sites; approximately 4,500 employees; manufactures injectable pharmaceutical products including oncology compounds; facility operates under FDA cGMP; oncology API manufacturing area: designated HD manufacturing suite with negative pressure differential, HEPA filtered exhaust, dedicated HVAC; cisplatin API synthesis and purification operations: cisplatin bulk API production via reaction of potassium tetrachloroplatinate(II) with ammonia in aqueous solution → precipitation, filtration, washing, drying; dry cisplatin API is white crystalline powder; bulk packaging operations: cisplatin API transfer from dryer to bins, bin-to-bin transfer, sieve analysis, sampling, and vial fill preparation; airborne cisplatin monitoring: SKC Millipore cellulose ester filter (MCEF) + ICP-MS analysis for Pt; 8-hr TWA monitoring during API bin transfer and vial fill setup: 0.0018 mg/m³ as cisplatin (Pt-equivalent: 0.0018 × 0.6502 = 0.001170 mg/m³ as Pt = 58.5% of OSHA soluble Pt PEL 0.002 mg/m³); displayed (÷10): 0.00018 mg/m³ as cisplatin]).

The Surface 1 subject is a 47-year-old male Pfizer Kalamazoo oncology manufacturing process operator (19-year Pfizer Kalamazoo tenure; primary duties: cisplatin API bin transfer, filter cake sampling, and vial fill preparation in HD manufacturing suite; personal protective equipment: Pfizer HD protocol includes Tyvek coverall, double nitrile gloves, half-face respirator with combination HEPA/OV cartridge during bin transfer; Cority occupational health: SCr (serum creatinine) monitored annually as part of heavy metal exposure surveillance — most recent 1.2 mg/dL (upper normal for age/weight); audiometric monitoring: annual air conduction audiogram — most recent: 4 kHz notch at right ear (25 dB HL); referenced in Cority as "likely recreational noise"; no cisplatin cumulative Pt body burden tracking in Cority). Cority: "SKC MCEF + ICP-MS (cisplatin [CAS 15663-27-1]; 8-hr TWA; Pfizer oncology manufacturing suite): 0.00018 mg/m³. OSHA PEL [CAS 15663-27-1]: no specific OSHA PEL found for this substance. ACGIH TLV-TWA [CAS 15663-27-1]: not established. NIOSH REL [CAS 15663-27-1]: no entry in NIOSH Pocket Guide. Result: no applicable OEL for CAS 15663-27-1 — compliance status cannot be determined by OEL comparison." Actual 0.0018 mg/m³ as cisplatin: Pt-equivalent 0.001170 mg/m³ = 58.5% of OSHA soluble Pt PEL 0.002 mg/m³ — approaching PEL; NIOSH HD Category 1 C-PEC + CSTD + PPE requirements not appearing in Cority OEL output; SCr elevation trend not linked to Pt nephrotoxicity; 4 kHz audiometric notch not linked to cisplatin ototoxicity.

Consequence pathway: Cisplatin at 58.5% of OSHA soluble Pt PEL masked by CAS cross-reference failure → Cority outputs "no applicable OEL"; NIOSH HD Category 1 C-PEC and CSTD requirements invisible; 47M operator with early audiometric changes (4 kHz notch) and upper-normal SCr — cumulative Pt body burden ototoxicity and nephrotoxicity risk not evaluated; Pt body burden urine monitoring not triggered.

Surface 2 — Fresenius Kabi Wilson NC Generic Injectable Cisplatin Manufacturing AI (Downward + MW Conversion Gap)

At Fresenius Kabi USA LLC Wilson NC ([Wilson NC 27893; Wilson County NC; Fresenius Kabi: global pharmaceutical manufacturer specializing in generic injectables; Wilson NC: major US injectable manufacturing site; FDA 503B outsourcing facility designation; manufactures cisplatin injection USP in 50 mg/50 mL and 200 mg/200 mL single-use vials (1 mg/mL concentration); manufacturing process: aqueous cisplatin solution preparation in stainless steel vessels → sterile filtration → vial filling under ISO 5 laminar air flow → lyophilization or terminal sterilization → visual inspection → final release; primary cisplatin exposure events: bulk cisplatin API weighing (precision analytical balance in HD weighing booth with negative pressure and HEPA exhaust), solution preparation (cisplatin API dissolved in saline in closed vessel with magnetic stirring → loading hatch opens briefly for API addition), and vial fill line setup/changeover; SKC MCEF + ICP-MS monitoring during typical cisplatin batch production (100L batch size; 20 kg cisplatin API per batch); 8-hr TWA: 0.0014 mg/m³ as cisplatin; Pt-equivalent: 0.0014 × 0.6502 = 0.000910 mg/m³ as Pt = 45.5% of OSHA soluble Pt PEL; displayed (÷10): 0.00014 mg/m³]).

Surface 2 subject: 43-year-old female Fresenius Kabi Wilson NC pharmaceutical process operator (15-year Fresenius Kabi Wilson tenure; primary duty: cisplatin injection vial fill operations and API weighing; personal protective equipment: Fresenius Kabi HD protocol for NIOSH HD Category 1 drugs; double nitrile gloves with outer chemo-rated Ansell TouchNTuff 92-600 gloves; closed gown; face shield during API weighing; VelocityEHS occupational health: renal function (SCr, BUN, urinalysis) annually; most recent BUN 18 mg/dL, SCr 0.9 mg/dL [normal]; urine Pt (biomonitoring): not performed — VelocityEHS system does not prompt Pt biomonitoring for cisplatin operations because OEL compliance determined as COMPLIANT). VelocityEHS: "SKC MCEF + ICP-MS (cisplatin; 8-hr TWA; Fresenius Kabi Wilson): 0.00014 mg/m³. Platinum soluble salts (as Pt) PEL: 0.002 mg/m³. 0.00014/0.002 = 7% — COMPLIANT." MW Pt-fraction conversion NOT applied: 0.00014 mg/m³ as cisplatin compared directly to 0.002 mg/m³ as Pt without × 0.6502 correction. Correct comparison: 0.00014 × 0.6502 = 0.0000910 mg/m³ as Pt = 4.55% — still within PEL at displayed concentration. But actual concentration: 0.0014 mg/m³ cisplatin × 0.6502 = 0.000910 mg/m³ as Pt = 45.5% of PEL — significant approach to OEL limit. VelocityEHS additionally retrieves soluble Pt PEL via generic "platinum" class lookup, not CAS 15663-27-1 direct retrieval — accidental match via class entry rather than correct CAS cross-reference.

Consequence pathway: Cisplatin 45.5% of OSHA soluble Pt PEL (actual) masked by ÷10 to 4.55% displayed; VelocityEHS retrieves PEL via class entry (not CAS cross-reference) and applies it without MW conversion; NIOSH HD Category 1 invisible; urine Pt biomonitoring not triggered by VelocityEHS HD compliance gap; 43F operator — no cumulative Pt burden tracking despite 15yr cisplatin manufacturing exposure.

Surface 3 — Stony Brook University Hospital Oncology Pharmacy Compounding AI (Downward + HD Controls Invisible)

At Stony Brook University Hospital Stony Brook NY ([101 Nicolls Road, Stony Brook NY 11794; Suffolk County NY; Stony Brook University Hospital: 619-bed academic medical center; NCI-Designated Cancer Center (Stony Brook Cancer Center); outpatient oncology pharmacy: high-volume cisplatin infusion preparation for NSCLC, bladder, and head-and-neck cancer protocols; cisplatin preparation operations: reconstitution of cisplatin injection concentrate vials (Accord Healthcare or Fresenius Kabi brand; 1 mg/mL concentrate; 50 mg/100 mL or 200 mg/200 mL vials) → dilution to appropriate volume per protocol (cisplatin 75 mg/m² in 250 mL NS; cisplatin 100 mg/m² in 1000 mL NS) using CSTD (Equashield II device); BSC: Class II Type B2 with direct exhaust to outdoors (100% exhaust, no recirculation); daily batch preparation volume: 15–25 cisplatin infusion bags; pharmacist tasks: CSTD-mediated transfer of cisplatin concentrate to infusion bag, labeling, clinical verification; needle-free CSTD used but physical connection/disconnection generates micro-aerosol at transfer spike; air monitoring: Stony Brook EHS program uses IOM sampler + ICP-MS for Pt during peak cisplatin preparation shift; 8-hr TWA: 0.00090 mg/m³ as cisplatin; Pt-equivalent: 0.00090 × 0.6502 = 0.000585 mg/m³ as Pt = 29.25% of OSHA soluble Pt PEL; displayed (÷10): 0.000090 mg/m³]).

Surface 3 subject: 38-year-old female Stony Brook University Hospital oncology pharmacist (11-year Stony Brook oncology pharmacy tenure; primary duty: oncology infusion preparation including cisplatin batch preparation; annual cisplatin infusion preparation volume: approximately 3,500–5,000 infusion bags; EHS Insight occupational health module: audiometric monitoring performed annually (OSHA 29 CFR 1910.95 noise standard program; cisplatin ototoxicity not linked to industrial noise monitoring program); most recent audiogram: bilateral mild high-frequency loss at 6 kHz and 8 kHz (15–20 dB HL bilateral); classified as age-related in EHS Insight; no cisplatin ototoxicity flag; renal function: SCr 0.8 mg/dL, BUN 14 mg/dL — not linked to cisplatin Pt body burden in EHS Insight; urine Pt biomonitoring: not performed). EHS Insight: "IOM sampler + ICP-MS (cisplatin [CAS 15663-27-1]; 8-hr TWA; Stony Brook oncology pharmacy BSC area): 0.000090 mg/m³. OSHA PEL: Platinum soluble salts (as Pt) 0.002 mg/m³. 0.000090/0.002 = 4.5% — COMPLIANT [MW Pt-fraction conversion not applied]. NIOSH: no REL for CAS 15663-27-1. ACGIH TLV: not established for CAS 15663-27-1. Overall: COMPLIANT." USP <800> C-PEC verification, CSTD usage documentation, and HD PPE compliance status not appearing in EHS Insight air monitoring compliance output; audiometric bilateral high-frequency loss not linked to cisplatin ototoxicity; no urine Pt biomonitoring triggered.

Consequence pathway: Cisplatin 29.25% of OSHA soluble Pt PEL (actual) masked as 2.925% (÷10 × 0.6502 not applied); EHS Insight: "4.5% — COMPLIANT"; NIOSH HD Category 1 C-PEC, CSTD, USP <800> invisible; 38F oncology pharmacist with bilateral high-frequency audiometric loss (unlinked to cisplatin ototoxicity in EHS Insight) and 11-year cumulative Pt exposure — no urine Pt biomonitoring, no ototoxicity-specific audiometric evaluation at 6–8 kHz.

Integrating Glyphward into Cisplatin and Platinum Compound AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CAS 15663-27-1 monitoring data ingestion point — before Cority at Pfizer Kalamazoo MI, VelocityEHS at Fresenius Kabi Wilson NC, and EHS Insight at Stony Brook University Hospital NY. Threshold 22 reflects: OSHA soluble Pt CAS cross-reference failure + NIOSH HD Category 1 OEL null-return + ACGIH CAS-specific gap + MW Pt-fraction conversion error [OSHA Z-1 "Platinum soluble salts (as Pt)" PEL 0.002 mg/m³ is not indexed under cisplatin CAS 15663-27-1 in AI OEL databases → AI query returns null or "no applicable PEL"; NIOSH HD Category 1 (established human carcinogen + reproductive toxicant + genotoxic per NIOSH 2016 HD List) is NOT an OEL → NIOSH Pocket Guide query for CAS 15663-27-1 returns no entry → AI outputs "NIOSH REL: none" while the actual NIOSH position mandates HD Category 1 engineering controls (C-PEC, CSTD, double-glove PPE per USP <800>) at every preparation regardless of airborne concentration — this is the most safety-critical NIOSH designation for cisplatin and it is structurally invisible to OEL-based AI; ACGIH TLV for "Platinum soluble salts" similarly not indexed under CAS 15663-27-1; MW Pt-fraction conversion (× 0.6502) required for correct comparison of mg/m³-as-cisplatin monitoring data to mg/m³-as-Pt OEL — AI applying direct comparison overestimates compliance margin by 1.54× even when the class PEL is correctly retrieved; ÷10 perturbation further reduces apparent concentrations 10×: 9 points]; IARC 2A carcinogenicity + nephrotoxicity (cumulative dose-dependent proximal tubular injury) + ototoxicity (irreversible cochlear outer hair cell destruction → SNHL) + reproductive toxicity (NIOSH HD Category 1 designation) [cisplatin: IARC Group 2A probably carcinogenic to humans — testicular cancer risk; occupational cisplatin exposure in pharmacy workers: oncology pharmacist/nurse case series (Sessink et al.; Zanini et al.) documenting urinary Pt elevations and chromosomal aberrations in workers with BSC and CSTD use; nephrotoxicity: cumulative Pt-DNA adducts in renal proximal tubular cells → CKD risk with chronic occupational low-dose exposure; ototoxicity: cochlear outer hair cell (OHC) destruction beginning at basal turn (high-frequency first) → bilateral SNHL at 4–8 kHz; progressive with cumulative Pt body burden; irreversible; reproductive: embryotoxic and teratogenic in animal studies; NIOSH HD Category 1 classification: 6 points]; Pfizer Kalamazoo MI + Fresenius Kabi Wilson NC + Stony Brook University Hospital Stony Brook NY [three named pharmaceutical and healthcare facilities covering the three primary cisplatin occupational exposure settings: oncology API synthesis, generic injectable manufacturing, and hospital pharmacy compounding]: 3 points; FIRST cisplatin NIOSH HD Category 1 OEL null-return CAS confusion AI attack (no prior Glyphward attack on NIOSH HD antineoplastic agents); FIRST platinum coordination compound CAS index gap documentation (CAS 15663-27-1 cisplatin vs "Platinum soluble salts" class entry in OSHA Z-1 and ACGIH TLV); FIRST USP <800> hazardous drug engineering controls (C-PEC, CSTD, PPE) structurally invisible to OEL-based AI compliance determination — the most widespread HD control standard in US healthcare not visible in any AI OEL platform output; FIRST MW Pt-fraction conversion gap (mg/m³ as cisplatin compound vs mg/m³ as Pt element) documented in AI OEL comparison architecture: 4 points. Total: 9+6+3+4 = 22.